Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia
暂无分享,去创建一个
C. Katlama | B. Autran | D. Costagliola | J. Capeau | M. Valantin | L. Assoumou | A. Marcelin | C. Soulié | A. Guihot | L. Campillo-Gimenez | J. Villemonteix | Priya Pajanirassa
[1] S. Vermund,et al. HIV and Noncommunicable Disease Comorbidities in the Era of Antiretroviral Therapy: A Vital Agenda for Research in Low- and Middle-Income Country Settings , 2014, Journal of acquired immune deficiency syndromes.
[2] C. Katlama,et al. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. , 2014, The Journal of antimicrobial chemotherapy.
[3] B. Clotet,et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection , 2014, AIDS.
[4] M. Fischl,et al. Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection. , 2013, The Journal of infectious diseases.
[5] G. d’Ettorre,et al. Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial , 2013, PloS one.
[6] S. Moe,et al. Effects of Switching From Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function: A Randomized, Controlled Trial , 2013, Journal of acquired immune deficiency syndromes.
[7] G. Guaraldi,et al. HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy , 2013, Drugs.
[8] M. Lederman,et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. , 2013, Blood.
[9] R. Paredes,et al. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. , 2013, The Journal of antimicrobial chemotherapy.
[10] N. Shaheen,et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure , 2013, AIDS.
[11] M. Nelson,et al. CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection , 2012, Molecular medicine.
[12] E. Ruiz-Mateos,et al. Effect of Maraviroc on HIV Disease Progression-Related Biomarkers , 2012, Antimicrobial Agents and Chemotherapy.
[13] D. Podzamczer,et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy , 2012, AIDS.
[14] E. Rosenberg,et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. , 2011, The Journal of infectious diseases.
[15] S. Lewin,et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.
[16] A. Lazzarin,et al. Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial , 2011, HIV clinical trials.
[17] S. Deeks,et al. HIV infection, inflammation, immunosenescence, and aging. , 2011, Annual review of medicine.
[18] J. Casanova,et al. Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors , 2010, Immunity.
[19] Sarah Palmer,et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.
[20] D. Cooper,et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials , 2010, The Lancet.
[21] A. Phillips,et al. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.
[22] T. Perneger,et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006 , 2008, HIV medicine.
[23] J. Benito,et al. CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. , 2004, AIDS research and human retroviruses.
[24] John W. Mellors,et al. New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.
[25] R. Landmann,et al. Human monocyte CD14 is upregulated by lipopolysaccharide , 1996, Infection and immunity.
[26] M. Lederman,et al. Residual immune dysregulation syndrome in treated HIV infection. , 2013, Advances in immunology.